Search Results for “EC” – Page 378 – media

GenScript and T-MAXIMUM partner for CAR-T cell therapy development

Genscript Biotech has formed a strategic collaboration agreement with T-MAXIMUM Biotech to develop CAR-T cell therapy. Leveraging GenScript’s CRISPR nucleic acid re-agents, the partnership will focus on developing T-MAXIMUM’s CAR-T cell therapy. GenScript research and development (R&D) and manufacturing vice-president Dr Li Hong stated: “Our R&D-to-GMP-level sgRNA will support their UCAR-T products for solid tumours. While CAR-T cell therapies have made remarkable strides in haematological tumours, addressing the unmet need for solid tumours remains crucial.” T-MAXIMUM will receive a number of CRISPR re-agents from GenScript. These will support the development of T-MAXIMUM’s universal CAR-T products from discovery to commercialisation. GenScript’s partnership with T-MAXIMUM will drive the latter’s strategic development plan, advancing products into Phase II clinical research and enabling market delivery up to 2027. T-MAXIMUM is currently focused on the development of its universal CAR-T cell therapy product, MT027, to treat recurrent high-grade gliomas. T-MAXIMUM CEO Dr Shang Xiaoyun stated: ...
- Source: drugdu
- 114
- August 14, 2023
【EXPERT Q&A】What might be the reasons for not closing deals despite following up with many clients?

Drugdu.com expert’s response: For foreign trade salespeople, every inquiry received is hard-won and should be treasured. However, inevitably among these inquiries, there will be phishing emails, junk inquiries, and even more seriously, potential scammers. Therefore, upon receiving an email, the immediate response is not advisable. Instead, it’s essential first to discern and analyze. How to handle and reply to inquiries more effectively is the key to success. 1. Determine authenticity: 01 Check the IP: Check the sender’s IP by right-clicking the email, selecting properties-details to view the IP address of the email. Determine its geographical location. Also, cross-reference the IP records in the website counter to observe whether the visitor clicked a link to enter the website or typed in your URL directly. 02 Consider the sending time: Look at the email sending time and account for time zone differences. Generally, no one would send emails in the middle ...
- Source: drugdu
- 203
- August 14, 2023
Foreign Trade Experience
Pfizer faces whistleblower lawsuit from former compliance manager who says he flagged possible fraud in China

After Pfizer allegedly fired a compliance manager for raising the flag on potential fraud activity in China, the former employee is hitting back. Frank Han, the former director of global compliance analytics at Pfizer, has filed a civil complaint against the drugmaker. In the California lawsuit, Han claims he was terminated for identifying potential Foreign Corrupt Practices Act (FCPA) issues within the company. Han worked for Pfizer from May 2017 to November 2022, according to the court documents. Back in 2021, Han says he discovered that Pfizer had spent “over ten times the amount of money” on potentially influential government officials (PIGOs) in China than the company had spent on those officials in other countries, the court documents state. Specifically, Pfizer spent $168 million on PIGOs in China between the second quarter of 2019 and the third quarter of 2021, Han’s work found. That compared to $12 million in the ...
- Source: drugdu
- 450
- August 12, 2023
Novo Nordisk spends $1bn to acquire weight loss drug developer Inversago.

Amongst fierce competition in the obesity space, Novo Nordisk has spent $1bn to acquire Inversago Pharma to shore up its weight loss treatment portfolio. The acquisition is expected to be completed by the end of 2023 and will hit the billion-dollar mark, subject to developmental and commercial milestones. The deal, which comes a month after Eli Lilly acquired Versanis and its lead weight loss candidate, bimagrumab, in a $1.9bn deal, will include Inversago’s lead asset INV-202, an oral cannabinoid receptor type-1 (CB1) inverse agonist. Novo Nordisk said it intends to use the candidate for patients with obesity and obesity-related complications. Canada-based Inversago demonstrated the weight loss potential of the candidate in a Phase Ia trial by blocking the CB1 receptor, which plays an important role in appetite regulation and metabolism. INV-202 is currently in a Phase II trial for diabetic kidney disease (NCT05514548). Prior to the 10 August announcement, Novo ...
- Source: drugdu
- 111
- August 12, 2023
JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Joint Committee on Vaccination and Immunisation (JCVI) has announced its advice in relation to details surrounding the eligibility of this autumn’s COVID-19 booster vaccine. As the UK COVID-19 vaccination programme enters its third autumn season, the Committee has advised offering the booster to those at high risk of serious disease and who are therefore more likely to benefit from the vaccination. This includes all adults aged 65 years and older, residents in care homes for older adults, those aged six months to 64 years in a clinical risk group, those aged 16 to 64 years who are carers and staff working in care homes for adults. The COVID-19 booster vaccine helps to protect against severe illness, hospitalisations and deaths from COVID-19. Dr Mary Ramsay, director of public health programmes at the UK Health Security Agency, said the COVID-19 virus is “circling more widely over the winter months, with the ...
- Source: drugdu
- 107
- August 12, 2023
Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Novartis has shared positive top-line results from two late-stage studies evaluating its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. Affecting 40 million people worldwide, CSU is a debilitating and unpredictable condition characterised by the occurrence of itchy hives and/or deep tissue swelling that lasts for six weeks or longer. H1-antihistamines are the first-line treatment for the condition; however, approximately 60% of patients are inadequately controlled by these alone and continue to live with the distressing symptoms of CSU. Novartis’ remibrutinib works by blocking the cascade of BTK, an enzyme central to the release of histamine and, when spontaneously activated, plays a critical role in the symptoms associated with CSU. The ongoing phase 3 REMIX-1 and REMIX-2 trials met their primary endpoint of absolute change from baseline in weekly urticaria activity score (UAS7) at week 12, demonstrating clinically ...
- Source: drugdu
- 110
- August 12, 2023
WHO Classifies EG.5 as COVID-19 ‘Variant of Interest’

By Gabrielle Tétrault-Farber and Leroy Leo (Reuters) – The World Health Organization on Wednesday classified the EG.5 coronavirus strain circulating in the United States and China as a “variant of interest” but said it did not seem to pose more of a threat to public health than other variants. The fast-spreading variant, the most prevalent in the United States with an estimated more than 17% of cases, has been behind upticks in the virus across the country and also has been detected in China, South Korea, Japan and Canada, among other countries. “Collectively, available evidence does not suggest that EG.5 has additional public health risks relative to the other currently circulating Omicron descendent lineages,” the WHO said in a risk evaluation. A more comprehensive evaluation of the risk posed by EG.5 was needed, it added. COVID-19 has killed more than 6.9 million people globally, with more than 768 million confirmed ...
- Source: drugdu
- 104
- August 12, 2023
【EXPERT Q&A】How to promote pharmaceutical intermediates?

Drugdu.com expert’s response: Promoting pharmaceutical intermediates essentially hinges on market positioning and the intended target audience. Here are some effective methods to promote pharmaceutical intermediates: 1.Participate in Professional Expos: This provides an excellent opportunity to meet potential clients and showcase your products. You can display product samples and engage in face-to-face business discussions. 2. Establish an Official Website: By setting up an official website, you can showcase your company’s capabilities, product details, and enhance your corporate image. 3. Online Marketing: For instance, post product information on industry-specific websites. Using Search Engine Optimization (SEO) and Search Engine Marketing (SEM) strategies can boost the online visibility of your products. 4. Cold-call Potential Customers: Take the initiative to reach out to companies that might be interested. This can be done via emails or phone calls. 5. Promote through Industry-specific Platforms: Drugdu.com is a dedicated platform for medical imports and exports. It caters to industry ...
- Source: drugdu
- 221
- August 11, 2023
pharmaceutical intermediates
A promising new treatment for hematological malignancies

A new research perspective was published in Oncotarget’s Volume 14 on August 7, 2023, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.” In their new perspective, researchers Daniel Morillo, Gala Vega and Victor Moreno from Hospital Fundación Jiménez Díaz discuss Cyclin-dependent kinases (CDK) in hematological malignancies. CDKs belong to a family of serine/threonine kinases that need to form heterodimeric complexes with cyclins to perform their functions. These kinases are involved in multiple processes within cells, including cell cycle, apoptosis, transcription and differentiation. These kinases are often overexpressed in different malignancies, making them potential targets for new drugs. Most hematological malignancies are characterized by overexpression of certain cancer-promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors suppress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their potential synergism with other drugs. In its first ...
- Source: drugdu
- 112
- August 11, 2023
“Visual-movement” neurons in the brain help individuals to stay focused on rewarding tasks

Trying to finish your homework while the big game is on TV? “Visual-movement” neurons in the front of your brain can help you stay focused, according to a new study from neuroscientists in the Perelman School of Medicine at the University of Pennsylvania. In the study, published recently in Neuron, the scientists sought to illuminate the neural mechanism that helps the brain decide whether to focus visual attention on a rewarding task or an alluring distraction. By analyzing neuron activity in animal models as they faced this kind of attentional conflict, the researchers discovered that a pattern of coordinated activity called “beta bursts” in a set of neurons in the lateral prefrontal cortex (LPFC)-;a section in the front of the brain responsible for motivation and rewards-;appears to have a major role in keeping attention task-focused, essentially by suppressing the influence of the distracting stimulus. Bijan Pesaran PhD (senior author, the ...
- Source: drugdu
- 119
- August 11, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.